COMUNICADO: Fiasp®▼, a new, ultra-fast acting mealtime insulin is available for the treatment of diabetes in adults (y 2)

Publicado 27/03/2017 9:02:01CET

[**] Information provided about Fiasp(R) is based on the marketing authorisation received from the European Commission and these details may vary in individual markets.

Further information 
Katrine Sperling 

Asa Josefsson 
Peter Hugreffe Ankersen 

Hanna Ogren 

Anders Mikkelsen 

Kasper Veje (US) 

(Logo: )